Centre National De La Recherche Scientifique

Universite Claude Bernard – Lyon1

Hospices Civils De Lyon

Institut National De La Sante Et De La Recherche Medicale

Centre Leon Berard

Internationa—drug—development—biotech

International-drug-development-biotech

Centre De Lutte Contre Le Cancer Léon Bérard

Jean-Jacques Diaz

Jean-Christophe Saurin

Manuel Rosa-Calatrava

Claudine Vermot-Desroches

Julien Textoris

Serge Petit

Marie Alexandra Albaret

Hichem Claude Mertani

Boris Vuillermoz

Laurence Josset

Jean-Xavier Roca-Martinez

Manuel Rosa-calatrava

The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.

Anti-CK8 antibodies for use in the treatment of colorectal cancers

Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.

Pharmaceutical or veterinary antiviral compositions

The invention relates to antibodies specific to human CK8 and to pharmaceutical compositions for preventing and treating colorectal cancers. The invention also relates to methods for identifying colorectal cancers with an invasive and/or metastatic phenotype including detecting the cleavage of the C-terminal portion of human CK8 on the surface of tumor cells.

Anti-CK8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes

Growing community of inventors

Venissieux, France

Jean-Jacques Diaz